The NYC-based biotechnology company uses computational chemistry and structure-based technologies to develop novel small molecules for hematologic malignancies. By combining disease, genetics, and structural biology insights with an advanced computational drug discovery platform, Ajax Therapeutics creates precisely designed small molecule therapeutics that address significant unmet needs for patients with hematologic malignancies.